Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Peripheral blood T cell TRBV3-1 gene detection kit, and applications thereof in breast cancer curative effect prediction

A kit, breast cancer technology, applied in the biological field to achieve good results

Pending Publication Date: 2017-12-15
CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Trastuzumab (trastuzumab, trade name: Herceptin) is a humanized monoclonal antibody against HER2. It has been widely used in the treatment of HER2-positive breast cancer patients, and many patients have benefited from it. However, data have confirmed About 60% of patients with HER2 positive overexpression did not respond to trastuzumab treatment, and about 15% of patients developed tumors after receiving trastuzumab-based combination therapy transfer process

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peripheral blood T cell TRBV3-1 gene detection kit, and applications thereof in breast cancer curative effect prediction
  • Peripheral blood T cell TRBV3-1 gene detection kit, and applications thereof in breast cancer curative effect prediction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1 Screening for gene markers associated with breast cancer

[0042] 1. Sample collection

[0043] 1.1 Inclusion criteria

[0044] The study included 26 patients with pathologically confirmed ER / PR-negative HER2-positive invasive breast cancer, with an average age of 48 years and clinical stages of II-III patients. 21 patients received 4-6 cycles of trastuzumab combined with paclitaxel + carboplatin therapy (TCH) neoadjuvant therapy, 5 patients received trastuzumab combined with epirubicin + paclitaxel (ATH) neoadjuvant therapy. The patient had not previously received any other anti-tumor therapy (including radiotherapy, chemotherapy, targeted therapy, and endocrine therapy) for breast cancer. Among them, 11 patients achieved pathological complete remission (pCR) and 15 patients had non-complete remission (non-pCR).

[0045] 1.2 Collection of samples and clinical data

[0046] After obtaining the informed consent of the patients, peripheral blood samples were...

Embodiment 2

[0075] Example 2 QPCR sequencing to verify the differential expression of TRBV3-1

[0076] 1. Sample collection

[0077] The study included 80 patients with pathologically confirmed ER / PR-negative HER2-positive invasive breast cancer, with an average age of 47 years, and the patients were in clinical stage II-III. Thirty-two patients received neoadjuvant therapy of trastuzumab combined with epirubicin and paclitaxel (ATH), and 48 patients received neoadjuvant therapy of trastuzumab combined with paclitaxel and carboplatin (TCH). According to statistics, there were 49 patients with non-pCR and 31 patients with pCR.

[0078] 2. RNA extraction and quality analysis

[0079] 2.1 Extraction of RNA

[0080] Total RNA was extracted using the RNA extraction kit from Promega, and the specific operations were performed according to the instructions.

[0081] 2.2 Quality analysis of RNA samples

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a peripheral blood T cell TRBV3-1 gene detection kit, and applications thereof in breast cancer curative effect prediction. High-throughput sequencing of peripheral blood T cell acceptor (TCR) beta chain CDR3 zone DNA of patients receiving treatment is carried out, it is found that the number of patients (pCR) with complete remission effect after curative effect of treatment of TRBV3-1 gene is obviously lower than the number of patients with non-pathological complete remission (non-pCR), it is shown that TRBV3-1 can be taken as a marker used for prediction of HER2 positive breast cancer patient trastuzumab combined chemotherapy preoperative therapy effect, people capable of benefiting from trastuzumab combined chemotherapy adjuvant therapy are selected, and customized treatment of HER2 positive breast cancer is realized.

Description

technical field [0001] The invention relates to the field of biotechnology, and relates to a peripheral blood T cell TRBV3-1 gene detection kit and its application in predicting the curative effect of breast cancer. Background technique [0002] Breast cancer is one of the most common malignant tumors in women. According to statistics, there are about 1.35 million breast cancer patients in the world every year, of which 540,000 are new cases, and about 500,000 people die from the disease every year. At present, breast cancer mainly includes five types, namely, luminal epithelial (expressing normal mammary luminal epithelial hormone receptors, cytokeratin and related genes) type A (Luminal A), luminal epithelial type B (Luminal B, compared with A type) Low hormone receptor level, high histological grade), HER-2 overexpression type, basal-like (basal-like (expression of breast epithelial basal-like or stem cell-related genes) and normal breast-like type. HER2 overexpression i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68
CPCC12Q1/6886C12Q2600/106C12Q2600/158
Inventor 徐兵河马飞王文娜陈文挺王玉奇管彦芳
Owner CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com